- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| AZITRA Aktie jetzt für 0€ handeln | |||||
| Mi | Azitra receives U.S. patent for Netherton syndrome treatment | 1 | Investing.com | ||
| Mi | Azitra secures U.S. patent for ATR-12 skin disease treatment program | 2 | Seeking Alpha | ||
| 23.03. | Azitra, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.03. | Azitra Shares Jump 55% | 3 | RTTNews | ||
| 20.03. | Azitra CEO-backed private placement priced up to $10.5M, potential $20.9M; stock jumps 90% | 3 | Seeking Alpha | ||
| 19.03. | Azitra secures up to $31.4M to fund cosmetic protein research | 2 | Investing.com | ||
| 19.03. | Azitra sichert sich bis zu 31,4 Mio. USD zur Finanzierung kosmetischer Proteinforschung | 10 | Investing.com Deutsch | ||
| 13.03. | Azitra, Inc.: Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement | 452 | PR Newswire | BRANFORD, Conn., March 13, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 13.03. | NYSE warnt Azitra vor Delisting aufgrund von Eigenkapitaldefizit | 2 | Investing.com Deutsch | ||
| 13.03. | Azitra receives NYSE delisting warning over equity shortfall | 1 | Investing.com | ||
| 13.03. | Azitra receives notice of non-compliance with NYSE American Listing standards | 2 | Seeking Alpha | ||
| 13.03. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.02. | Azitra GAAP EPS of -$2.25 beats by $0.23 | 3 | Seeking Alpha | ||
| 27.02. | Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates | 484 | PR Newswire | BRANFORD, Conn., Feb. 27, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 27.02. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.02. | Azitra, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 06.02. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.01. | Azitra, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 17.12.25 | Azitra receives NYSE American approval of listing compliance plan | 1 | Seeking Alpha | ||
| 17.12.25 | Azitra receives approval for NYSE American compliance plan | 3 | Investing.com |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ALUMIS | 23,660 | 0,00 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 19,390 | 0,00 % | Monte Rosa Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| SUMMIT THERAPEUTICS | 18,080 | 0,00 % | H.C. Wainwright cuts Summit Therapeutics stock price target on trial risk | ||
| ADMA BIOLOGICS | 8,150 | -0,24 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen | |
| BEAM THERAPEUTICS | 32,350 | +0,09 % | Beam Therapeutics Inc. - 10-Q, Quarterly Report | ||
| CG ONCOLOGY | 69,64 | +0,03 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates | Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant... ► Artikel lesen | |
| QIAGEN | 28,210 | -1,00 % | Infineon haussiert, Qiagen schmiert ab: DAX-Ausblick | Nach Verlusten zu Beginn der Woche hat sich der DAX am Donnerstag wieder nach oben aufgemacht. So legte das größte deutsche Börsenbarometer auf Wochensicht doch noch 164 Punkte zu und schloss +0,68%... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 29,500 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers | Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approachesPhase 1 initiation expected in the second half of... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 330,13 | +0,03 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| MODERNA | 49,455 | +7,22 % | Moderna: Hantavirus-Schlagzeilen treiben Impfstoff-Aktie an | Das Hantavirus ist auf einem kleinen Kreuzfahrtschiff im Atlantik ausgebrochen. Die Weltgesundheitsorganisation (WHO) hat inzwischen fünf von acht Verdachtsfällen als offizielle Fälle bestätigt. Aus... ► Artikel lesen | |
| IMMUNOVANT | 28,950 | +0,03 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,315 | -0,15 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,170 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TRAWS PHARMA | 2,170 | -0,46 % | Traws Pharma, Inc.: Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections | NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 134,38 | +0,02 % | Inhibrx rises on upcoming interim mid-stage data for head and neck cancer asset |
Das Unternehmen AZITRA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,230 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AZITRA INC finden Sie auf Wallstreet Online.